Ampio Pharmaceuticals updates Optina dose finding study

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE +3.4%) reports interim results from a dose finding trial of Optina in DME.

Ultimately, the IDRC recommended the continuation of the trial as "it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect [and] there were no significant safety concerns."

Once the trial is complete, the company will immediately initiate an open label extension study using the determined optimum dose. (PR)